Cite
Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
MLA
Su, Na‐Yun, et al. “Efficacy and Safety of Vonoprazan‐based Dual Therapy and Esomeprazole‐based Dual Therapy in Eradicating Primary Helicobacter Pylori Infection: A Propensity Score Matching Analysis.” Helicobacter, vol. 28, no. 5, Oct. 2023, pp. 1–9. EBSCOhost, https://doi.org/10.1111/hel.13003.
APA
Su, N., Shi, Q., Mei, H., Hu, J., Liu, Y., Liu, H., Liu, H., Guo, Y., Wang, X., & Lan, C. (2023). Efficacy and safety of vonoprazan‐based dual therapy and esomeprazole‐based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis. Helicobacter, 28(5), 1–9. https://doi.org/10.1111/hel.13003
Chicago
Su, Na‐Yun, Qing Shi, Hao Mei, Jie Hu, Yu‐Xiang Liu, Han‐Ning Liu, Heng‐Qi Liu, Yan Guo, Xing‐wei Wang, and Chun‐Hui Lan. 2023. “Efficacy and Safety of Vonoprazan‐based Dual Therapy and Esomeprazole‐based Dual Therapy in Eradicating Primary Helicobacter Pylori Infection: A Propensity Score Matching Analysis.” Helicobacter 28 (5): 1–9. doi:10.1111/hel.13003.